SB 218795

Research use only, not for human use.

SB 218795 is an effective and selective antagonist of NK3 with a Ki 13 nM for hNK3 which is about 90-fold and 7000-fold selectivity over hNK2 and hNK1.

SB 218795 is an effective and selective antagonist of NK3 with a Ki 13 nM for hNK3 which is about 90-fold and 7000-fold selectivity over hNK2 and hNK1.(In Vitro):SB 218795 (3-30 nM) antagonizes the contractile responses senktide-induced in a surmountable and concentration-dependent manner.(In Vivo):In rabbits, SB 218795 (0.25-1 mg/kg; i.v.) inhibits NK3 receptor-mediated pupillary constriction by maximum inhibition of 78%.

SB 218795 (3-30 nM) antagonizes the contractile responses induced by the NK3 receptor agonist senktide in a surmountable and concentration-dependent manner.SB 218795 (0.3-3?μM) does not affect the contractile responses of the NK3 receptor agonist [MePhe7]-NKB in the rabbit iris sphincter muscle.

SB?218795 (0.25-1?mg/kg; i.v.) inhibits Senktide-induced miosis in rabbits by the maximum inhibition of 78%.

——

GPCR/G Protein

Neurokinin Receptor

——

——

——

174635-53-1

396.446

C25H20N2O3

>98% (HPLC)

In Vitro:?DMSO : 250 mg/mL (630.61 mM)

COC(=O)[C@@H](NC(=O)c1cc(nc2ccccc12)-c1ccccc1)c1ccccc1

——

(-20℃)

With Ice Pack

≥ 2 years